Final Glance: Biotechnology companies
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
Midday Glance: Biotechnology companies
AP - Thu Jul 31, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Early Glance: Biotechnology companies
AP - Thu Jul 31, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 12:10PM CDT
Vertex Pharma (VRTX) posted a wider second quarter loss and also missed revenue expectations.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Celgene (CELG) Breaks Through Resistance at $88.45
Comtex SmarTrend(R) - Wed Jul 30, 9:30AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $87.80 today and has reached the first level of resistance at $88.45. Should the shares continue to rise, the resistance pivots of $89.17 and $90.54 will be of interest.
Amgen Beats on Q2 Earnings & Revs, Ups View & Plans Job Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 8:20AM CDT
While Amgen's (AMGN) second quarter results were impressive, the company's restructuring plan remained in focus.